C. Fleurinck

542 total citations
28 papers, 106 citations indexed

About

C. Fleurinck is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, C. Fleurinck has authored 28 papers receiving a total of 106 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Rheumatology, 18 papers in Immunology and 5 papers in Hematology. Recurrent topics in C. Fleurinck's work include Spondyloarthritis Studies and Treatments (23 papers), Psoriasis: Treatment and Pathogenesis (16 papers) and Rheumatoid Arthritis Research and Therapies (16 papers). C. Fleurinck is often cited by papers focused on Spondyloarthritis Studies and Treatments (23 papers), Psoriasis: Treatment and Pathogenesis (16 papers) and Rheumatoid Arthritis Research and Therapies (16 papers). C. Fleurinck collaborates with scholars based in United States, Belgium and Germany. C. Fleurinck's co-authors include Lianne S. Gensler, Xenofon Baraliakos, Ute Massow, Atul Deodhar, Désirée van der Heijde, Natasha de Peyrecave, Alan Kivitz, Marina Magrey, Tetsuya Tomita and Christine de la Loge and has published in prestigious journals such as Gastroenterology, Antimicrobial Agents and Chemotherapy and Annals of the Rheumatic Diseases.

In The Last Decade

C. Fleurinck

25 papers receiving 105 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Fleurinck United States	5	86	63	34	9	7	28	106
Iain McInnes Denmark	3	71 0.8×	61 1.0×	39 1.1×	6 0.7×	7 1.0×	3	98
Musaab Elmamoun United Kingdom	5	63 0.7×	64 1.0×	38 1.1×	4 0.4×	7 1.0×	8	94
Olga Ziouzina Canada	3	95 1.1×	65 1.0×	35 1.0×	3 0.3×	5 0.7×	5	98
Laurence Carton France	4	99 1.2×	59 0.9×	29 0.9×	3 0.3×	1 0.1×	12	110
Michael Zisapel Israel	4	49 0.6×	23 0.4×	19 0.6×	2 0.2×	4 0.6×	9	66
G. De Brabanter Belgium	2	42 0.5×	31 0.5×	18 0.5×	23 2.6×	3 0.4×	4	81
Natalia Manilo Denmark	5	137 1.6×	88 1.4×	55 1.6×	6 0.7×		8	157
Stylianos Tomaras Germany	5	16 0.2×	34 0.5×	47 1.4×	16 1.8×	5 0.7×	9	81
Vanesa Cosentino Argentina	5	42 0.5×	50 0.8×	11 0.3×	6 0.7×	8 1.1×	8	78
José Chávez-Corrales Peru	4	74 0.9×	59 0.9×	39 1.1×	6 0.7×		5	87

Countries citing papers authored by C. Fleurinck

Since Specialization

Citations

This map shows the geographic impact of C. Fleurinck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Fleurinck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Fleurinck more than expected).

Fields of papers citing papers by C. Fleurinck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Fleurinck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Fleurinck. The network helps show where C. Fleurinck may publish in the future.

Co-authorship network of co-authors of C. Fleurinck

This figure shows the co-authorship network connecting the top 25 collaborators of C. Fleurinck. A scholar is included among the top collaborators of C. Fleurinck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Fleurinck. C. Fleurinck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deodhar, Atul, Victoria Navarro‐Compán, Denis Poddubnyy, et al.. (2025). Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open. 11(1). e005081–e005081. 2 indexed citations

Panés, Julián, Brian G. Feagan, Jarosław Kierkuś, et al.. (2025). 1118a: A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF AGMB-129 IN PATIENTS WITH FIBROSTENOTIC CROHN’S DISEASE: INTERIM RESULTS FROM THE STENOVA TRIAL. Gastroenterology. 169(1). S–2086.

Merola, Joseph F., Philip J. Mease, Atul Deodhar, et al.. (2024). P171 Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies. Lara D. Veeken. 63(Supplement_1). 1 indexed citations

Brown, Matthew A., Martín Rudwaleit, F. van Gaalen, et al.. (2024). Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Annals of the Rheumatic Diseases. 83(12). 1722–1730. 11 indexed citations

Dubreuil, Maureen, Victoria Navarro‐Compán, Annelies Boonen, et al.. (2024). Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD Open. 10(2). e004202–e004202. 4 indexed citations

Navarro‐Compán, Victoria, Sofía Ramiro, Atul Deodhar, et al.. (2024). Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. 10(2). e004040–e004040. 1 indexed citations

Cella, David, Christine de la Loge, Shien Guo, et al.. (2024). The Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation. Journal of Patient-Reported Outcomes. 8(1). 92–92. 4 indexed citations

Rudwaleit, Martín, Matthew Brown, Nigil Haroon, et al.. (2024). P163 Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Lara D. Veeken. 63(Supplement_1). 1 indexed citations

Navarro‐Compán, Victoria, Martín Rudwaleit, Maureen Dubreuil, et al.. (2024). Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies. The Journal of Rheumatology. 52(1). jrheum.2024–223. 1 indexed citations

10.

Deodhar, Ajita, D. van der Heijde, Walter P. Maksymowych, et al.. (2024). POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 83. 913–914. 2 indexed citations

11.

Proft, Fabian, Désirée van der Heijde, Xenofon Baraliakos, et al.. (2023). POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2. Annals of the Rheumatic Diseases. 82. 874–875. 2 indexed citations

12.

Baraliakos, Xenofon, Atul Deodhar, Désirée van der Heijde, et al.. (2023). Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Annals of the Rheumatic Diseases. 83(2). 1–15. 25 indexed citations

13.

Baraliakos, Xenofon, Sofía Ramiro, Martín Rudwaleit, et al.. (2023). POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2. Annals of the Rheumatic Diseases. 82. 875–876. 1 indexed citations

14.

Rudwaleit, Martín, Matthew A. Brown, F. van Gaalen, et al.. (2023). POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS. 614.2–615. 2 indexed citations

15.

Deodhar, Atul, Sofía Ramiro, Martín Rudwaleit, et al.. (2023). AB1000 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL RESPONSE CRITERIA AND LOWER LEVELS OF DISEASE ACTIVITY WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION AND HRQOL IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM TWO PHASE 3 STUDIES ON BIMEKIZUMAB. Annals of the Rheumatic Diseases. 82. 1721–1721. 1 indexed citations

16.

Poddubnyy, Denis, Lianne S. Gensler, Philip J. Mease, et al.. (2023). AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 82. 1686–1687. 1 indexed citations

17.

Baraliakos, Xenofon, Victoria Navarro‐Compán, Denis Poddubnyy, et al.. (2023). POS0246 BIMEKIZUMAB REDUCED MRI INFLAMMATORY LESIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 82. 357–357.

18.

Baraliakos, Xenofon, Atul Deodhar, Désirée van der Heijde, et al.. (2023). POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 82. 873–874. 1 indexed citations

19.

Ramiro, Sofía, Denis Poddubnyy, Philip J. Mease, et al.. (2023). POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 82. 358–359.

20.

Baraliakos, Xenofon, Atul Deodhar, Maxime Dougados, et al.. (2022). Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study. Arthritis & Rheumatology. 74(12). 1943–1958. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact